Dexmedetomidine-propofol-remifentanil Anaesthesia and Reactivity to Noxious Stimuli
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
|Official Title:||The Effect of Dexmedetomidine on Reactivity to Noxious Stimuli During Propofol-remifentanil Anaesthesia and Surgery|
- Physiological reaction to noxious stimulus [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]Nociception-associated changes in EEG, EMG, Entropy Index values, BIS Index values, morphology of plethysmogram or ECG, heart rate, or hear rate variability.
|Study Start Date:||November 2009|
|Study Completion Date:||March 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Active Comparator: Dexmedetomidine
Analgo-sedative, adjuvant of propofol anesthesia
Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Other Name: Precedex. CAS 113775476.Drug: Saline
Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
The patients are randomized to receive either dexmedetomidine or saline infusion before and during anaesthesia (dexmedetomidine 0.1 mcg/kg within 10 minutes, thereafter 0.7 mcg/kg/h until 30 min after skin incision).
Multi-channel EEG, Entropy, BIS, multi-channel EMG, ECG, and plethysmogram are recorded on computer. Anaesthesia and surgery associated events are annotated on computer.
Time points of endotracheal intubation, skin incision, and course of surgery well be analyzed in detail. Additionally, tetanic stimulus of ulnar nerve will be applied for each patient, and reactions to the stimulus will be analyzed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01076790
|Tampere University Hospital|
|Tampere, Finland, 33521|
|Study Chair:||Arvi Yli-Hankala, MD||Tampere University Hospital|
|Principal Investigator:||Arvi Yli-Hankala, MD||Tampere University Hospital|